的见解 & 资源
Adapting CDMO Capabilities to Support the Development and 商业ization of Orphan Drugs and Novel Therapies
As more novel therapies and orphan drugs fill the drug development pipeline, small-scale CDMO capabilities have become an increasingly common need for sponsors developing and commercializing new drug entities.
Navigating New Regulations in Biobanking for Clinical Studies and Research Projects
让我们一起来听教授的演讲. 乔纳森Douxfils, QUALIblood的首席执行官兼联合创始人, as he explains the latest regulations in biobanking and their impact on clinical studies, 研究人员可能需要在他们的项目中实施哪些改变, and the potential challenges in complying with these new regulations.
Two Steps Forward, One Step Back: The Dance Toward IND Submission in Early Development
尽管环境在不断变化, the success rate for drug candidates during early development continues to be low. 然而, when you understand the pitfalls that can impede early development, 可以有效地管理相关的风险, ultimately driving your program and your organization toward long-term commercial success.
在国家授权正规彩票平台, we have always believed that our people are our greatest asset. They’re our scientific experts – creative and analytical thinkers – and the backbone of the services we provide for our clients.
Understanding the Importance of Solid Form Screening in Drug Development
Solid state properties of active pharmaceutical ingredients (API) are a critical attribute of any drug product and significantly impact the drug’s efficacy, 安全, 和稳定性. 选择, development and scaling-up of a solid-state form with desirable properties is therefore critical for the success of drug development programs.
准备IND提交时, drug developers must carefully consider multiple components of their program: analytical challenges, 制造和工程控制, 运载系统, 和更多的. Watch this webinar to see 国家授权正规彩票平台 experts discuss tips for optimizing your early development program
我们的科学家擅长建立联系. Start a conversation today and see what it’s like to work with a collaborative CDMO.与专家取得联系